A Phase 2 interventional study of Deucravacitinib in Pityriasis Rubra Pilaris
Completed Phase 2 NCT06444399
Study Description
Evaluating the Safety and Effectiveness of Deucravacitinib in Treating Pityriasis Rubra Pilaris
Study Details
- Registry ID:
- NCT06444399
- Conditions:
- Pityriasis Rubra Pilaris
- Phase:
- Phase 2
- Target Enrollment:
- 7 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.